{"id":14526,"date":"2012-02-01T09:30:00","date_gmt":"2012-02-01T08:30:00","guid":{"rendered":"http:\/\/www.fedaiisf.it\/anno-doro-per-aziende-di-generici\/"},"modified":"2012-02-01T09:30:00","modified_gmt":"2012-02-01T08:30:00","slug":"anno-doro-per-aziende-di-generici","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/anno-doro-per-aziende-di-generici\/","title":{"rendered":"Golden year for generic companies"},"content":{"rendered":"

Goldman Sachs averages +18% in industry turnover<\/p>\n

<\/span><\/em><\/strong><\/p>\n

<\/p>\n

 <\/p>\n

<\/span><\/em><\/strong><\/p>\n

It could indeed be a golden year for generic drug makers, according to a Goldman Sachs report. Indeed, the Healthcare team led by Jami Rubin notes that 2012 will be exceptional for these industries, given the numerous patent expirations. <\/p>\n

<\/font><\/font><\/span><\/p>\n

It is calculated that large companies will earn double-digit revenue growth, equal to +18% on average. However, the US business appears to be rapidly maturing due to fewer generics coming to market first. In other words, Goldman Sachs assures, as 'designer' companies fare, so will 'generic' ones a few years later. And post-2013 remains an unknown factor for the sector, given that the potential 'drivers' of future growth are those that raise the most uncertainty, such as biosimilars and generics outside the USA. <\/p>\n

<\/font><\/font><\/span><\/p>\n

The banking giant also welcomes the expansion of Teva, the world's leading generics maker, into the world of branded medicines, including its recent hiring of Bristol-Myers Squibb 'veteran' Jeremy Levin as CEO, as well as its biosimilars partnerships with Watson and Amgen.<\/p>\n

<\/font><\/font><\/span><\/p>\n

Barbara Di Chiara \u2013 February 1, 2012 \u2013 PharmaKronos<\/p>\n

<\/span><\/em><\/p>\n

Up to +30% sale of seasonal medicines in pharmacies<\/span><\/strong><\/p>\n

<\/span><\/strong><\/p>\n

Freezing week ahead and we run for cover<\/p>\n

<\/span><\/em><\/strong><\/p>\n

The cold seems to have really arrived and the effects are immediately starting to be seen. Sales of me are booming in Italian pharmacies<\/p>","protected":false},"excerpt":{"rendered":"

Goldman Sachs, in media +18% nel fatturato delle industrie di settore   Potrebbe essere davvero un anno d’oro per i produttori di farmaci generici, secondo un report di Goldman Sachs. Il team Healthcare guidato da Jami Rubin rileva infatti che il 2012 sarà eccezionale per queste industrie, date le numerose scadenze di brevetto. Si calcola …<\/p>","protected":false},"author":1,"featured_media":9846,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[90],"tags":[],"class_list":["post-14526","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-fedaiisf-archivio-storico"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/14526","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=14526"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/14526\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/9846"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=14526"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=14526"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=14526"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}